Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) fell 3.9% during mid-day trading on Tuesday . The company traded as low as $5.73 and last traded at $5.74, with a volume of 344,845 shares traded. The stock had previously closed at $5.97.

A number of research firms recently commented on RPTP. FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a report on Sunday, June 12th. Wedbush reaffirmed a “neutral” rating and set a $4.00 price target on shares of Raptor Pharmaceutical Corp. in a report on Friday, May 6th. Zacks Investment Research cut Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Cowen and Company reaffirmed a “buy” rating and set a $8.00 price target on shares of Raptor Pharmaceutical Corp. in a report on Sunday, April 17th. Finally, Leerink Swann cut their price target on Raptor Pharmaceutical Corp. from $18.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, March 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $11.00.

The firm’s market capitalization is $489.66 million. The stock has a 50 day moving average price of $5.55 and a 200 day moving average price of $4.69.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last released its earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.17). The company had revenue of $27.47 million for the quarter, compared to analyst estimates of $27.17 million. During the same quarter in the previous year, the firm earned ($0.24) EPS. The firm’s revenue was up 34.3% on a year-over-year basis. On average, equities analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.98) EPS for the current fiscal year.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Globeflex Capital L P raised its position in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 116.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 209,787 shares of the company’s stock after buying an additional 113,016 shares during the period. Globeflex Capital L P owned 0.25% of Raptor Pharmaceutical Corp. worth $1,091,000 as of its most recent SEC filing.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.